Navigation Links
Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Date:9/17/2008

PRINCETON, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the UBS Global Life Sciences Conference being held from September 22-25, 2008 at the Grand Hyatt Hotel in New York City. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company on Wednesday, September 24, 2008, from 4:00 PM - 4:30 PM (ET).

To access a live webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

Chief Financial Officer

kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
2. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
3. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
4. Pharmasset Receives Notice of Allowance
5. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
6. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
7. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
8. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
9. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
10. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
11. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2020)... ... 2020 , ... Healthcare Management Solutions, LLC (HMS) ... can be found at: https://hcmsllc.com/ . The healthcare and IT consulting company ... and this rebrand reflects HMS’ continued excellence and impressive evolution in the marketplace. ...
(Date:6/23/2020)... ... ... One size fits all may work for a facemask these days, but ... not work as an overall response to the virus causing the need for the ... or another, from plummeting stock markets and rising unemployment on a macro scale to ...
(Date:6/19/2020)... ... , ... Food Equality Initiative (FEI), a nonprofit with the mission ... disease announced the first of the “ For the Health” webinar series, A Conversation ... 19, 2020, from 11:00, am EST - 12:00 pm EST. , Intentionally planned ...
Breaking Medicine Technology:
(Date:6/24/2020)... ... June 24, 2020 , ... At Allerio we have chosen to do things ... communications. We knew it had to be portable, it had to be reliable, it ... to work. , We are proud to announce that Allerio has passed all FCC ...
(Date:6/24/2020)... Ga. (PRWEB) , ... June 24, 2020 , ... ... and population health management, today announced that Wexford Physician Hospital Organization (PHO) has ... quality and cost goals within the framework of value-based care. Use of Population ...
(Date:6/24/2020)... ... June 24, 2020 , ... Skyroam , the developer of patented virtual ... , the leading provider of enterprise software for testing laboratories, in which its Skyroam ... new Portable Disease Surveillance Lab (PDSL) kit. , “Stopping the spread of COVID-19 is ...
(Date:6/23/2020)... ... June 23, 2020 , ... Oak Street Health, a ... announced further plans for nationwide expansion in 2020 with the company’s first centers in ... open two locations in Brooklyn, N.Y., and a new center in Jackson, Miss. ...
(Date:6/23/2020)... British Columbia (PRWEB) , ... June 23, 2020 , ... ... that Dr. Mike Hart has been named as the President of North ... of experience in plant based therapy, including owning and operating his own family medicine ...
Breaking Medicine News(10 mins):